New hope for blood cancer patients: stronger chemo before transplant
NCT ID NCT02250937
First seen Nov 01, 2025 · Last updated Apr 17, 2026 · Updated 26 times
Summary
This study is testing if adding a drug called venetoclax to the standard chemotherapy given before a donor stem cell transplant works better for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to kill more cancer cells before the transplant to help prevent the cancer from coming back. Researchers are comparing two different timing schedules for the drugs to see which one is more effective and safer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.